VRP.L Regulatory News (VRP)

VRP.L Information

There is currently no data for VRP

REMOVE ADS

Director Shareholding

15 Oct 2012 14:01

Director Shareholding

15 October 2012 - London, UK - Verona Pharma plc (AIM: VRP.L) (the "Company") has received notification that on 12 October 2012, Jan-Anders Karlsson, CEO and a director of the Company, acquired an interest in 150,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 4.5 pence per share.

Following the acquisition, Dr. Karlsson will have an interest in the Company of 150,000 Ordinary Shares, representing 0.05% of the Company's issued ordinary share capital.

-Ends-

For more information please contact:

Verona Pharma plc Tel: 020 7863 3300 Jan-Anders Karlsson, CEO info@veronapharma.com WH Ireland Group Plc Tel: 020 7220 1650 Chris Fielding Chris.fielding@WH-Ireland.Co.UK

XLON

Date		Source	Headline
4th Oct 2013	12:06 pm	PRN	Placing of shares
30th Sep 2013	7:00 am	PRN	Half-yearly Report
23rd Sep 2013	7:00 am	PRN	Notice of Results
10th Sep 2013	7:00 am	PRN	Clinical data presented at ERS
5th Sep 2013	7:01 am	PRN	Presentations at ERS
5th Sep 2013	7:00 am	PRN	Appointment of Richard Bungay as CFO
29th Jul 2013	10:13 am	PRN	Grant of Options
25th Jul 2013	1:23 pm	PRN	Director Shareholding
24th Jul 2013	5:58 pm	PRN	Holding(s) in Company
23rd Jul 2013	12:45 pm	PRN	Director Shareholding
24th Jun 2013	7:00 am	PRN	First patient dosed in clinical trial for VRP700
3rd Jun 2013	4:46 pm	PRN	Result of AGM
21st May 2013	4:00 pm	PRN	ATS Tuesday Presentation
20th May 2013	7:00 am	PRN	ATS Sunday Poster Presentations
16th May 2013	7:00 am	PRN	Presentations at ATS Conference
9th May 2013	8:05 am	PRN	Posting of Annual Report and AGM Notice
29th Apr 2013	7:00 am	PRN	New Clinical and Scientific Advisory Board Announced
26th Apr 2013	10:17 am	PRN	Director/PDMR Shareholding
15th Apr 2013	3:01 pm	PRN	Grant of Options
10th Apr 2013	3:07 pm	PRN	Director's Dealing
10th Apr 2013	10:23 am	PRN	Director Dealings
10th Apr 2013	7:00 am	PRN	Final Results
19th Mar 2013	1:56 pm	PRN	Holding(s) in Company
5th Mar 2013	7:00 am	PRN	RPL554 demonstrates airway anti-inflammatory activity
28th Feb 2013	7:00 am	PRN	Total Voting Rights
21st Feb 2013	2:35 pm	PRN	Holding(s) in Company
18th Feb 2013	2:53 pm	PRN	Result of General Meeting
31st Jan 2013	10:54 am	PRN	Placing and Equity Finance Facility
24th Jan 2013	2:09 pm	PRN	Notice of Interest
18th Jan 2013	10:18 am	PRN	Holding(s) in Company
4th Jan 2013	2:59 pm	PRN	Statement Regarding Share Price Movement
12th Nov 2012	11:38 am	PRN	Notice of Interest
15th Oct 2012	2:01 pm	PRN	Director Shareholding
12th Oct 2012	9:00 am	PRN	RPL554 Phase I/IIa data presented at ISAF 2012
26th Sep 2012	9:00 am	PRN	Investor Presentation
17th Sep 2012	10:44 am	PRN	New Option Scheme and Grant of Options
14th Sep 2012	7:00 am	PRN	Half-yearly Report
6th Sep 2012	7:00 am	PRN	Notice of Interim Results
4th Sep 2012	7:30 am	PRN	Verona Pharma: RPL554 COPD Data Presented at ERS
3rd Sep 2012	9:30 am	PRN	Notice of Interest
28th Aug 2012	7:00 am	PRN	US Patent Granted for Verona Pharma's RPL554
9th Jul 2012	7:00 am	PRN	Verona Pharma Investigates Anti-inflammatory - RPL554
1st Jun 2012	6:14 pm	PRN	Result of AGM
1st Jun 2012	11:30 am	PRN	CEO's Statement to Annual General Meeting
8th May 2012	4:56 pm	PRN	Posting of Annual Report
1st May 2012	7:00 am	PRN	Verona Pharma appoints new CEO
5th Apr 2012	7:00 am	PRN	Verona Pharma - Preliminary Unaudited Results
9th Mar 2012	7:00 am	PRN	Verona Pharma â€" First UK RPL554 anti-inflammatory trial
31st Jan 2012	7:00 am	PRN	Total Voting Rights
16th Jan 2012	12:19 pm	PRN	Notification of Major Interest in Shares

Latest Share Chat

VRP.L Regulatory News (VRP)

Director Shareholding

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending